一次情報の記録

重要トップライン結果

Kairos Pharma Announces Positive Interim Phase 2 Data for ENV-105 + Apalutamide in mCRPC

Kairos Pharma reported positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) plus apalutamide in mCRPC. The interim analysis showed a statistically significant improvement in progression-free survival compared to apalutamide alone. This is the first announcement of these results.

主要事実

提出
2026年11月5日 14:15
イベント
トップライン結果
方向
ポジティブ
アセット
carotuximab
信頼度
出典あり
無増悪生存期間
アパルタミド単独療法に対する統計的に有意な差

出典の抜粋

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company’s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mec

企業プレスリリース

このアセットの詳細

2026年11月3日
16:50
KAPAKairos Pharma, Ltd.

Kairos Pharmaが癌R&D 2026でENV-105第2相中間PFSデータを発表

学会発表SEC 8-K2 件の更新
Kairos Pharma Announces Positive Interim Phase 2 Data for ENV-105 + Apalutamide in mCRPC | SimianX AI